Why focus on uric acid?

Current Medical Research and Opinion

Volumn 31, Issue , 2015, Pages 3-7

  Johnson, Richard J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cardiovascular disease; Gout; Hyperuricemia; Uric acid

Indexed keywords

URIC ACID; ANTIGOUT AGENT;

ACUTE KIDNEY FAILURE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DISEASE COURSE; EMBASE; EPITHELIAL MESENCHYMAL TRANSITION; FATTY LIVER; HUMAN; HYPERURICEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY DISEASE; MACROALBUMINURIA; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; URIC ACID BLOOD LEVEL; WHITE COAT HYPERTENSION; ANIMAL; BLOOD; COMPLICATION; GOUT; HYPERTENSION; METABOLIC SYNDROME X; RISK FACTOR;

ANIMALS; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERTENSION; HYPERURICEMIA; METABOLIC SYNDROME X; RISK FACTORS; URIC ACID;

EID: 84942576157     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1087979     Document Type: Conference Paper

References (43)

1. Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens 2015; 33: 1729-41
2. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study. Ann Intern Med 1999; 131: 7-13
3. Wannamethee SG, Shaper AG, Whincup PH. Serum urate and the risk of major coronary heart disease events. Heart 1997; 78: 147-53
4. Vaccarino V, Krumholz HM. Risk factors for cardiovascular disease: one down, many more to evaluate. Ann Intern Med 1999; 131: 62-3
5. Beck LH. Requiem for gouty nephropathy. Kidney Int 1986; 30: 280-7
6. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: A systematic review and meta-Analysis. Arthritis Care Res (Hoboken) 2011; 63: 102-10
7. Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. Diabetes Care 2009; 32: 1737-42
8. Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003; 42: 474-80
9. Sirota JC, McFann K, Targher G, et al. Elevated serum uric acid levels are associated with nonalcoholic fatty liver disease independently of metabolic syndrome features in the United States: liver ultrasound data from the National Health and Nutrition Examination Survey. Metab Clin Exp 2013; 62: 392-9
10. Johnson RJ, Nakagawa T, Jalal D, et al. Uric acid and chronic kidney disease: which is chasing which? Nephr Dial Transpl 2013; 28: 2221-8
11. Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-6
12. Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005; 67: 1739-42
13. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol 2002; 282: F991-7
14. Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol 2008; 295: F1134-41
15. Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-Arginine treatment in experimental hyperuricemia. Am J Physiol 2007; 292: F1238-44
16. Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-Activated protein kinase and cyclooxygenase-2. Hypertension 2003; 41: 1287-93
17. Watanabe S, Kang DH, Feng L, et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002; 40: 355-60
18. Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. Hypertension 2003; 42: 247-52
19. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008; 300: 924-32
20. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012; 60: 1148-56
21. Ejaz AA, Dass B, Kambhampati G, et al. Lowering serum uric acid to prevent acute kidney injury. Med Hypotheses 2012; 78: 796-9
22. Ejaz AA, Kambhampati G, Ejaz NI, et al. Post-operative serum uric acid and acute kidney injury. J Nephrol 2012; 25: 497-505
23. Lapsia V, Johnson RJ, Dass B, et al. Elevated uric acid increases the risk for acute kidney injury. Am J Med 2012; 125: 302 e309-317
24. Hovind P, Rossing P, Tarnow L, et al. Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study. Diabetes 2009; 58: 1668-71
25. Rosolowsky ET, Ficociello LH, Maselli NJ, et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008; 3: 706-13
26. Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-97
27. Sanchez-Lozada LG, Tapia E, Rodriguez-Iturbe B, et al. Hemodynamics of hyperuricemia. Semin Nephrol 2005; 25: 19-24
28. Ryu ES, Kim MJ, Shin HS, et al. Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol 2013; 304: F471-80
29. Kosugi T, Nakayama T, Heinig M, et al. Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol 2009; 297: F481-8
30. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51-9
31. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010; 5: 1388-93
32. Cicerchi C, Li N, Kratzer J, et al. Uric acid-dependent inhibition of AMP kinase induces hepatic glucose production in diabetes and starvation: evolutionary implications of the uricase loss in hominids. FASEB J 2014; 28: 3339-50
33. Lanaspa MA, Cicerchi C, Garcia G, et al. Counteracting roles of AMP deaminase and AMP kinase in the development of fatty liver. PloS One 2012; 7: e48801
34. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and-independent fatty liver. J Biol Chem 2012; 287: 40732-44
35. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PloS One 2012; 7: e47948
36. Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011; 60: 1258-69
37. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol 2005; 25: 3-8
38. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 2013; 62: 3307-15
39. Johnson RJ, Andrews P. Fructose, uricase, and the back-To-Africa hypothesis. Evol Anthropol 2010; 19: 250-7
40. Tapia E, Cristobal M, Garcia-Arroyo FE, et al. Synergistic effect of uricase blockade plus physiological amounts of fructose-glucose on glomerular hypertension and oxidative stress in rats. Am J Physiol Ren Physiol 2013; 304: F727-36
41. Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci USA 2014; 111: 3763-8
42. Dehghan A, Kottgen A, Yang Q, et al. Association of three genetic loci with uric acid concentration and risk of gout: A genome-wide association study. Lancet 2008; 372: 1953-61
43. Yang Q, Kottgen A, Dehghan A, et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circulation Cardiovasc Genetics 2010; 3: 523-30